NantHealth (NASDAQ:NH) was downgraded by ValuEngine from a "buy" rating to a "hold" rating in a note issued to investors on Thursday, ValuEngine reports.
A number of other equities analysts have also commented on NH. BidaskClub raised NantHealth from a "buy" rating to a "strong-buy" rating in a report on Wednesday, June 24th. Zacks Investment Research raised NantHealth from a "sell" rating to a "buy" rating and set a $4.50 price target for the company in a report on Wednesday.
NantHealth stock opened at $5.10 on Thursday. NantHealth has a one year low of $0.45 and a one year high of $5.37. The business has a fifty day moving average price of $3.04 and a 200-day moving average price of $2.00. The firm has a market capitalization of $455.75 million, a P/E ratio of -28.33 and a beta of 1.91.
NantHealth (NASDAQ:NH) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.06) EPS for the quarter, hitting the Zacks' consensus estimate of ($0.06). The company had revenue of $18.18 million during the quarter, compared to the consensus estimate of $19.30 million. On average, research analysts forecast that NantHealth will post -0.34 earnings per share for the current year.
A number of large investors have recently bought and sold shares of the stock. Bank of America Corp DE bought a new stake in NantHealth during the fourth quarter valued at $31,000. Jane Street Group LLC bought a new stake in NantHealth during the first quarter valued at $54,000. Jacobs Levy Equity Management Inc. boosted its stake in NantHealth by 74.4% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 88,640 shares of the company's stock valued at $91,000 after buying an additional 37,812 shares during the period. Renaissance Technologies LLC boosted its stake in NantHealth by 28.1% during the fourth quarter. Renaissance Technologies LLC now owns 513,728 shares of the company's stock valued at $529,000 after buying an additional 112,605 shares during the period. Finally, JPMorgan Chase & Co. purchased a new stake in NantHealth during the first quarter valued at about $188,000. 3.33% of the stock is owned by institutional investors.
NantHealth Company Profile
NantHealth, Inc, together with its subsidiaries, operates as a healthcare technology company in the United States and internationally. The company engages in converging science and technology through an integrated clinical platform to provide health information at the point of care. It develops NantHealth solutions, including molecular profiling solutions, software, and hardware systems infrastructure, which integrates patient data management, bioinformatics, and molecular medicine to enable value-based care and evidence-based clinical practice.
Recommended Story: How is a Moving Average Calculated?
To view ValuEngine's full report, visit ValuEngine's official website.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
6 Stocks That May Not Survive the Coronavirus
Companies that are in a shaky financial position may sometimes attract investors in a bull market. Traders seeking a short-term profit can often use an oversold condition to capture a quick gain. But in a bear market, these companies frequently are left on the sidelines.
But a declining stock price by itself should not be enough to scare investors off. What investors really need to pay attention to is the company’s ability to finance existing debt or take on additional debt. Companies with low credit ratings face the problem of having too much debt on their books and an inability to finance it at more favorable rates.
That’s one reason we’ve put together this presentation that highlights 6 companies that may not survive the coronavirus. These companies have low stock prices. In fact, many of them are, or will be, in danger of being delisted if they cannot bring their stock above the $1 threshold. And on top of that, these companies each carry credit ratings of CCC+ or lower and are at risk of seeing those ratings even go lower.
Each of the companies presented here are considered to be among the weakest, if not the weakest, in their sector. If you have any of these falling knives in your portfolio now is the time to cut your losses and walk away.
View the "6 Stocks That May Not Survive the Coronavirus".